Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Disease Burden of Hepatitis C
4.2.2 Increasing Awareness and Advances in Diagnosis
4.2.3 Surge In Availability of Advanced Therapeutic Products
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Social Stigma and Undiagnosed Cases
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 Diagnosis
5.1.1.1 Liver Biopsy
5.1.1.2 Blood Tests
5.1.1.3 Other Diagnoses
5.1.2 Treatment
5.1.2.1 Antiviral Drugs
5.1.2.2 Immune Modulator Drugs
5.1.2.3 Other Treatments
5.2 By End-User
5.2.1 Hospitals and Clinics
5.2.2 Diagnostic Laboratory
5.2.3 Other End-Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Gilead Sciences, Inc.
6.1.2 AbbVie Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Merck & Co., Inc.
6.1.5 Novartis AG
6.1.6 Johnson & Johnson
6.1.7 GlaxoSmithKline plc
6.1.8 F. Hoffmann-La Roche Ltd
6.1.9 Eli Lilly and Company
6.1.10 Takeda Pharmaceutical Company Limited
6.1.11 Cipla Inc.
6.1.12 Daiichi Sankyo Company, Limited
6.1.13 Astellas Pharma Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS